

## **Oxis International, Inc. (OTCQB: OXIS) Announces Approval for Up-Listing to the OTCQB**

TAMPA, Fla., Jan. 29, 2015 -- Oxis International, Inc. (OTCQB: OXIS) (OXI.PA) a biotechnology company focused on cannabinoid therapy development and commercialization, is pleased to announce its approval and up-listing to the OTCQB.

Kay Simmons, Compliance Analyst for OTC Market Group sent (OTCQB: OXIS) Chairman & CEO Tony Cataldo the good news via email on Tuesday 1/28/15 stating ***"We would like to officially congratulate you on your approval to be upgraded to the OTCQB Marketplace on January 28, 2015! Your company has submitted all the mandatory documents and has successfully met all of the initial requirements."***

As an OTCQB listed company OXIS International, Inc. will be required to be current in their reporting and undergo an annual verification and management certification process, thus insuring a high level of compliance and transparency.

Chairman & CEO Tony Cataldo stated, "We have demonstrated over the past few months since new management has arrived, that we intend to bring Oxis to the forefront of the Biotech arena. In order to do so, Oxis needs to demonstrate that it is capable of maintaining the fundamental requirements to be taken seriously by the institutional investment community. Being uplisted to the OTCQB is one more step in that direction. I will continue to employ the same strategy I used when I created Lion Biotechnologies, Inc. (LBIO). To bring into Oxis high value biotech assets and scientists with the proper structure and fundamentals. (See January 11, 2015 Oxis announcement for P62 Multiple Myeloma)."

**About the OTCQB Marketplace:** The OTCQB is a venture stage marketplace for early stage and developing U.S. and international companies. Companies listed on the OTCQB must be current in their reporting and undergo an annual verification and management certification process.

**ABOUT OXIS BIOTECH, INC. - OXIS** is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world's leading cannabinoid researchers and institutions to advance its technologies.

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Oxis International, Inc.

CONTACT: Jon Barkman, Riverview Capital Enterprises, 866-845-0105